Cenexi annual summer shutdown impact
Cenexi's annual summer shutdown (4 weeks in France, 3 in Belgium) will continue to cause revenue loss and negative EBITDA in Q2 each year.
medium · management_commentaryGland Pharma Limited — Q2 FY24
Gland Pharma reported consolidated revenue of INR 1,373.4 crore in Q2 FY24, up 32% YoY, driven by Cenexi acquisition and US market recovery.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Enoxaparin pricing and volume pressure in ROW markets
ROW revenue declined 9% QoQ due to lower Enoxaparin volumes and pricing pressure from competition, with management noting very low margins.
medium · analyst_questionCenexi margin improvement timeline uncertain
Management declined to provide a timeline for Cenexi reaching 13-15% EBITDA margins, citing early stage of integration.
medium · analyst_questionPotential dilution from milestone income volatility
Milestone income (5% of ex-Cenexi revenue in Q2) can fluctuate between 5-10%, impacting quarterly comparability.
low · data_observation